Stockholders' Equity

3 Months Ended

Jan. 31, 2019

Note 10. Stockholders’ Equity

Changes in stockholders’ equity

Changes in stockholders’ equity were as follows for the three months ended January 31, 2019:

	Total Stockholders’ Equity
Balance as of October 31, 2018	$	82,194
Share-based compensation		987
Fee adjustment for common stock issuance		90
Common stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards		27
Preferred dividends – Series B		(800	)
Series C convertible preferred stock conversions		1,974
Series C preferred stock adjustment for beneficial conversion feature		6,586
Series C preferred stock redemption value adjustments		(8,550	)
Series D convertible preferred stock conversions		4,334
Series D preferred stock redemption accretion		(3,793	)
Impact of the adoption of Topic 606		(6,654	)
Other comprehensive income - foreign currency translation adjustments		7
Net loss		(17,548	)
Balance as of January 31, 2019	$	58,854

At Market Issuance Sales Agreement

On June 13, 2018, the Company entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc. and Oppenheimer & Co. Inc. (together, the “Agents”) to create an at the market equity program under which the Company from time to time may offer and sell shares of its common stock having an aggregate offering price of up to $50,000,000 through the Agents. Under the Sales Agreement, the Agent making the sales will be entitled to a commission in an amount equal to 3.0% of the gross proceeds from such sales. There were no sales under the Sales Agreement during the three months ended January 31, 2019.

Public Offerings and Outstanding Warrants

On May 3, 2017, the Company completed an underwritten public offering of (i) 12,000,000 shares of its common stock, (ii) Series C warrants to purchase 12,000,000 shares of its common stock and (iii) Series D warrants to purchase 12,000,000 shares of its common stock. The Series C warrants have an exercise price of $1.60 per share and a term of five years. The Series D warrants were all exercised prior to October 31, 2018. No shares of common stock were issued upon exercise of the Series C warrants during the first three months of fiscal year 2019.

On July 12, 2016, the Company closed on a registered public offering of securities to a single institutional investor pursuant to a placement agent agreement with J.P. Morgan Securities LLC. In conjunction with the offering, the Company issued 7,680,000 Series A Warrants, all of which remained outstanding as of January 31, 2019, with an exercise price of $5.83 per share.

The following table summarizes outstanding warrant activity during the three months ended January 31, 2019:

	Series A Warrants		Series C Warrants
Balance as of October 31, 2018		7,680,000		11,569,364
Warrants exercised		—		—
Warrants expired		—		—
Balance as of January 31, 2019		7,680,000		11,569,364